OneMedRadio interviewed Thomas Braun, CEO of Verisante Technologies [CVE:VRS], a medical device company committed to commercializing innovative systems for the early detection of cancer.
ThermoGenesis Sees Explosive Growth Opportunities in Stem Cells
Mel Engle, CEO of ThermoGenesis [NASDAQ: KOOL] recently discussed with OneMedRadio, the company’s stem cell products and FDA approval that may have groundbreaking implications for the stem cell market.
InVivo Therapeutics Treats the Spinal Cord Itself, A Novel Technology
Frank Reynolds, President and CEO of InVivo Therapeutics describes the company’s strategy in bringing its unique spinal cord injury (SPI) products to market.
Arun Menawat Discusses Novadaq Technologies, a Surgical Imaging Company
Novadaq Technologies (TSX:NDQ) President & CEO Arun Menawat, Ph.D was interviewed by OneMedRadio and discusses the roll out of his surgical imaging technology.
Inovio yields long-term immune responses from cervical cancer vaccine
Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.
ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
Emergent BioSolutions Acquires Rights To Lymphoma Drug
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
YM BioSciences Receives Orphan Drug Designation In EU For Myelofibrosis Treatment
YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.
